KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Short term Debt: 2015-2024

Historic Short term Debt for BeOne Medicines (ONC) over the last 8 years, with Dec 2024 value amounting to $851.5 million.

  • BeOne Medicines' Short term Debt fell 5.85% to $813.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $813.3 million, marking a year-over-year decrease of 5.85%. This contributed to the annual value of $851.5 million for FY2024, which is 23.70% up from last year.
  • As of FY2024, BeOne Medicines' Short term Debt stood at $851.5 million, which was up 23.70% from $688.4 million recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Short term Debt registered a high of $851.5 million during FY2024, and its lowest value of $297.9 million during FY2022.
  • Its 3-year average for Short term Debt is $612.6 million, with a median of $688.4 million in 2023.
  • As far as peak fluctuations go, BeOne Medicines' Short term Debt tumbled by 30.33% in 2022, and later spiked by 131.10% in 2023.
  • Yearly analysis of 5 years shows BeOne Medicines' Short term Debt stood at $335.0 million in 2020, then increased by 27.63% to $427.6 million in 2021, then crashed by 30.33% to $297.9 million in 2022, then spiked by 131.10% to $688.4 million in 2023, then increased by 23.70% to $851.5 million in 2024.